Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

摘要

In a recently published article in Gynecologic Oncology, O'Malley, et al., describe the outcome of a single institution non-randomized retrospective chart review of patients treated with either single agent weekly paclitaxel (n = 29) or the combination of weekly paclitaxel plus bevacizumab (n = 41) in "heavily pretreated recurrent epithelial ovarian cancer" [1 ]. The paper's title and abstract conclude that the combination strategy "significantly improves progression-free survival".